The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
Abstract
OBJECTIVES: To assess the incidence and risk factors for hepatotoxicity associated with nevirapine. DESIGN: A prospective cohort study in a teaching and referral hospital involving all consecutive patients who were prescribed a nevirapine-containing antiretroviral regimen between September 1997 and May 2000. METHOD: Cutaneous and hepatic adverse reactions and clinical hepatitis were assessed. Blood analysis including plasma HIV-1 RNA CD4 cell counts, liver chemistry tests, and serology for hepatitis B and C viruses. Hepatotoxicity was defined as an increase of at least threefold in serum alanine aminotransferase or aspartate aminotransferase levels compared with baseline values. RESULTS: Of a total of 610 patients, 82 (13.4%) were antiretroviral naive when commencing nevirapine, and 46.2 and 8.9% were coinfected with hepatitis C and B viruses, respectively. Median duration of exposure to nevirapine was 8.7 months (interquartile range 3.4--14.3). Hepatotoxicity developed in 76 (12.5%), an incidence of 13.1/100 person-years. Kaplan--Meier estimated incidence of hepatotoxicity at 3, 6 and 12 months was 3.7, 9.7 and 20.1%, respectively. In seven (1.1%) patients, hepatotoxicity was associated with clinical hepatitis, which was reversible upon discontinuation of therapy. Multivariate analysis identified the duration of prior exposure to antiretroviral drugs, hepatitis C virus, and higher baseline levels of alanine aminotransferase as independent risk factors for hepatotoxicity. CONCLUSIONS: Hepatotoxicity but not clinical hepatitis was common in HIV-1-infected patients receiving nevirapine-containing regimens and the incidence steadily increased over time. Prolonged exposure to any antiretroviral therapy, coinfection with hepatitis C virus and abnormal baseline levels of alanine aminotransferase identified patients at a higher risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Sulkowski, M. S. (2000) · JAMA · doi:10.1001/jama.283.1.74 · Cited by 950
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998) · AIDS · doi:10.1097/00002030-199814000-00004 · Cited by 847
den Brinker, M., Wit, F. W. N. M., Wertheim-van Dillen, P. M. E., Jurriaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Jan Weverling, G., et al. (2000) · AIDS · doi:10.1097/00002030-200012220-00011 · Cited by 390
Structural interventions in public health
Blankenship, K. M., Bray, S. J., & Merson, M. H. (2000) · AIDS · doi:10.1097/00002030-200006001-00003 · Cited by 382
John, M., Flexman, J., & French, M. A. H. (1998) · AIDS · doi:10.1097/00002030-199817000-00010 · Cited by 251
Savès, M., Vandentorren, S., Daucourt, V., et al. (1999) · AIDS · doi:10.1097/00002030-199912030-00002 · Cited by 148
Fullilove, R. E., Green, L., & Fullilove, M. T. (2000) · AIDS · doi:10.1097/00002030-200006001-00010 · Cited by 83
Johnson, S., & Baraboutis, J. G. (2000) · JAMA · doi:10.1001/jama.284.21.2722 · Cited by 71
Severe Hepatic Failure Related to Nevirapine Treatment
Cattelan, A. M., Erne, E. M., Salatino, A., Trevenzoli, M., Carretta, G., Meneghetti, F., & Cadrobbi, P. (1999) · Clinical Infectious Diseases · doi:10.1086/520242 · Cited by 70
Cited by
Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., & Pau, A. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00001 · Cited by 482
Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., et al. (2002) · AIDS · doi:10.1097/00002030-200204120-00001 · Cited by 444
Hepatitis C in the HIV-Infected Person
Sulkowski, M. S., & Thomas, D. L. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00012 · Cited by 405
Soriano, V., Puoti, M., Sulkowski, M., Cargnel, A., Benhamou, Y., Peters, M., Mauss, S., Bräu, N., Hatzakis, A., Pol, S., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3281084e4d · Cited by 349
A Paper-Based Multiplexed Transaminase Test for Low-Cost, Point-of-Care Liver Function Testing
Pollock, N. R., Rolland, J. P., Kumar, S., Beattie, P. D., Jain, S., Noubary, F., Wong, V. L., Pohlmann, R. A., Ryan, U. S., & Whitesides, G. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003981 · Cited by 326
Metadata
- Authors
- Martínez, E., Blanco, J. L., Arnaiz, J. A., Pérez-Cuevas, J. B., Mocroft, A., Cruceta, A., Marcos, M. A., Milinkovic, A., García-Viejo, M. A., Mallolas, J., Carné, X., Phillips, A., & Gatell, J. M.
- Venue
- AIDS
- Published
- 2001-07
- Volume
- 15
- Issue
- 10
- Pages
- 1261-1268
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2013907757
- Cited by
- 349
- References
- 11
- FWCI
- 24.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. https://app.cochat.ai/papers/10.1097/00002030-200107060-00007
- The paper
- Martínez, E., Blanco, J. L., Arnaiz, J. A., Pérez-Cuevas, J. B., Mocroft, A., Cruceta, A., Marcos, M. A., Milinkovic, A., García-Viejo, M. A., Mallolas, J., Carné, X., Phillips, A., & Gatell, J. M. (2001). Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. https://doi.org/10.1097/00002030-200107060-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.